Comments
Jubilant Life Sciences has reported a profit of ₹143.43 crore for the third quarter ended December 31, up from ₹26.69 crore in the corresponding quarter last year.
Shyam S. Bhartia, Chairman and Managing Director, said: “The performance (of the third quarter) reflects the strength of our diversified portfolio of businesses.” Total income registered 10 per cent growth at ₹1,442.78 crore in the quarter against ₹1,306.39 crore a year ago.
He added the company expects to perform better due to new product launches under solid dosage formulations, scaling up of speciality pharmaceuticals and higher volume in vitamins and acetyl businesses.
It said the ingredients segment drove revenue growth during the quarter on the back of better price and higher volumes. The drug-maker’s consolidated revenue rose 10 per cent year-on-year.
“We expect revenue growth due to strong pipeline in active pharmaceutical ingredients and solid dosage formulations, new product launches, and robust order book in sterile injectables,” the company said. Earnings per share stood at ₹9 against ₹1.68
On Thursday, the company’s scrip closed at ₹132.45 on the BSE, up 0.91 per cent.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.